The company has completed treatment of 25% of patients in the STAR trial of its medical device, SiPore15, and is well on track to finalize results by Q4 of this year.
The company also reports that treatment compliance is good and the safety profile continues to look positive.
STAR aims to demonstrate that the specially engineered mesoporous silica particle (MSP) can achieve a significant reduction in key cardio-metabolic risk factors – blood sugar, blood lipids and body fat composition – in both prediabetics and newly diagnosed type 2 diabetics.
“We are delighted that enrolment in STAR has progressed smoothly, enabling us to be on track for reporting results in October as previously stated. All of the patients have already received the orally-administered particles, which are intended to safely reduce blood sugar and other risk factor levels in prediabetic and newly diagnosed type 2 diabetics and pave the way towards regulatory approval,” says Sana Alajmovic, Co-Founder & CEO of Sigrid Therapeutics.
Photo: The Sigrid Therapeutics team